Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;17(5):360-363.
doi: 10.1002/jhm.12798. Epub 2022 Feb 28.

Clinical progress note: Indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients

Suchita Shah Sata  1   2 , Susan E Spratt  3 , Daniel L Edmonston  4   5 , Neha Pagidipati  5   6
Affiliations

Clinical progress note: Indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients

Suchita Shah Sata et al. J Hosp Med. 2022 May.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Salah HM, Al'Aref SJ, Khan MS, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021;232:10-22. doi:10.1016/j.ahj.2020.10.064
    1. Rawshani A, Rawshani A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;377(3):300-301. doi:10.1056/NEJMc1706292
    1. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243-255. doi:10.1016/j.jacc.2020.11.008
    1. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. doi:10.1136/bmj.m4573
    1. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9

LinkOut - more resources